High levels of TNFα in patients with COVID-19 refractory to tocilizumab

por Danlos, F.X., Ackermann, F., Rohmer, J., Roumier, M., Marabelle, A., Michot, J.M.
Publicado 2021

PB2102: PHASE 2 RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PLAMOTAMAB COMBINED WITH TAFASITAMAB (TAFA) + LENALIDOMIDE (LEN) VS TAFA+LEN IN REL...

por Michot, J.-M., Koh, Y., Lee, P., Jin, J., Clynes, R., Kye, S., Chiarella, M., Patel, K.
Publicado 2022

Seroconversion rate after vaccination against COVID-19 in patients with cancer—a systematic review

por Corti, C., Antonarelli, G., Scotté, F., Spano, J.P., Barrière, J., Michot, J.M., André, F., Curigliano, G.
Publicado 2022

Médicaments utilisés dans la prise en charge de l’infection à SARS-CoV-2 : étude rétrospective des principales associations à risque d’interactions médicamenteuses et des effets in...

por Dubois, A., Féral, A., Pain, J.-B., Michot, J., Fansi Ndengoue, D., Benomar, A., Clou, E., Debrix, I.
Publicado 2022

1694P Discovery of circulating biomarkers in COVID-19 patients undergoing anti-IL6R immunotherapy

por Michot, J-M., Dozio, V., Danlos, F-X., Vasse, M., Rohmere, J., Roumier, M., Pommeret, F., Kishazi, E., Marabelle, A., Escher, C., Kakalacheva-Beeler, K.
Publicado 2020

Bamlanivimab + etesevimab therapy induces SARS-CoV-2 immune escape mutations and secondary clinical deterioration in COVID-19 patients with B-cell malignancies

por Pommeret, F., Colomba, J., Bigenwald, C., Laparra, A., Bockel, S., Bayle, A., Michot, J.-M., Hueso, T., Albiges, L., Tiberghien, P., Marot, S., Jary, A., Lacombe, K., Barlesi, F., Griscelli, F., Colomba, E.
Publicado 2021

Tocilizumab, an anti-IL-6 receptor antibody, to treat COVID-19-related respiratory failure: a case report

por Michot, J.-M., Albiges, L., Chaput, N., Saada, V., Pommeret, F., Griscelli, F., Balleyguier, C., Besse, B., Marabelle, A., Netzer, F., Merad, M., Robert, C., Barlesi, F., Gachot, B., Stoclin, A.
Publicado 2020

Severe COVID-19 in patients with hematological cancers presenting with viremia

por Michot, J.M., Hueso, T., Ibrahimi, N., Pommeret, F., Willekens, C., Colomba, E., Francis, S., Bayle, A., Cournède, P.H., Merad, M., Foulon, S., Albiges, L., Gachot, B., Barlesi, F., Soria, J.C., Ribrag, V., Griscelli, F.
Publicado 2021

1639P Impact of COVID-19 on ongoing oncological and hematological treatment strategy

por Bayle, A., Ouali, K., Colomba, E., Ibrahimi, N., Foulon, S., Gachot, B., Willekens, C., Stoclin, A., Merad, M., Griscelli, F., Sun, R., Ammari, S., Michot, J-M., André, F., Scotté, F., Besse, B., Soria, J-C., Barlesi, F., Albiges, L., Pommeret, F.
Publicado 2021

1617P Sustained cancer clinical trial activity during the COVID-19 pandemic

por Bayle, A., Baldini, C., Romano, P. Martin, Michot, J-M., Champiat, S., Bahleda, R., Gazzah, A., Marabelle, A., Verlingue, L., Geraud, A., Morel, D., Michiels, S., Ribrag, V., Hollebecque, A., Albiges, L., Besse, B., Soria, J-C., Massard, C., Barlesi, F., Postel-Vinay, S.
Publicado 2021